Correlation Analysis of Serum Complement Level and Prognosis in Diagnosis of Aggressive Non-Hodgkin Lymphoma.
10.19746/j.cnki.issn.1009-2137.2025.01.014
- Author:
Bin-Bin DING
1
;
Na-Na LI
1
;
Bai DONG
1
;
Zi-Jian LI
2
Author Information
1. The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, Gansu Province, China.
2. Department of Hematology, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China.
- Publication Type:Journal Article
- Keywords:
complement； aggressive non-Hodgkin lymphoma； prognosis
- MeSH:
Humans;
Lymphoma, Non-Hodgkin/blood*;
Prognosis;
Complement C3/metabolism*;
Complement C4/metabolism*;
ROC Curve;
Male;
Female;
Middle Aged;
Adult;
Aged
- From:
Journal of Experimental Hematology
2025;33(1):101-107
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the relationship between serum complement levels at diagnosis and prognosis in patients with aggressive non-Hodgkin lymphoma(NHL).
METHODS:The clinical data of 102 patients with aggressive non-Hodgkin lymphoma diagnosed in the First Hospital of Lanzhou University from February 2017 to March 2023 were selected to analyze the correlation between serum complement C3 and C4 levels and prognosis of patients with aggressive NHL at the time of initial diagnosis. The optimal cut-off point of C3 and C4 were obtained by calculating the Jorden index through the receiver operating characteristic（ROC） curve, and 102 patients were divided into low C3 group (C3< 1.07) and high C3 group (C3≥1.07), low C4 group (C4< 0.255) and high C4 group (C4≥0.255). The effects of serum C3 and C4 levels on the prognosis of these patients were analyzed.
RESULTS:ROC curve analysis showed that the area under the curve (AUC) of C3 and C4 in predicting the prognosis of aggressive NHL patients was 0.634 (95%CI ：0.525-0.743；P =0.025) and 0.651 (95%CI ：0.541-0.761；P =0.012), respectively. The optimal cut-off points for C3 and C4 were 1.07 and 0.255, respectively. K-M survival analysis showed that groups with high C3 and C4 levels had shorter progression-free survival (PFS) (P =0.0079; P =0.0092) and overall survival (OS) (P =0.021; P =0.021). Multivariate Cox analysis showed that high level serum complement C3 (HR=2.37, 95%CI : 1.07-5.24, P =0.034) and age ≥60 years (HR=2.34, 95%CI : 1.11-4.95, P =0.025) were independent risk factors for PFS in patients with aggressive NHL. High level complement C3 (HR=2.37, 95%CI : 1.09-5.13, P =0.029) and age ≥60 years at diagnosis (HR=2.40, 95%CI : 1.13-5.13, P =0.024) were independent risk factors for OS in patients with aggressive NHL.
CONCLUSION:The level of serum complement C3 at diagnosis is one of the prognostic factors in patients with aggressive NHL.
